Ribobio Secures Over RMB 200 Million in New Financing Round Led by Mingxin Capital

Investment Circle (ID: pedaily2012) August 8th, by reporter, Suzhou Ribo Life Science Co., Ltd. ("Ribo Life Science" or "the Company") announced that it has recently completedOver 200 million yuanA new round of private equity financing. This round of financing was led byLed by Mingxin Capital, with participation from Kunshan High-Tech Venture Capital, Kunshan Guoke Venture Capital, Chouqin Venture Capital, Panlin Capital, Langma Peak Venture Capital, and Shenzhen Xinchuang Medical Cooperation.Completed with the participation of well-known investment institutions. The funds raised this time will be mainly used to accelerate the advancement of the company's self-developed clinical pipeline in therapeutic areas such as cardiovascular, metabolic, renal, and liver diseases, deepen the innovation and product development of the extrahepatic delivery technology platform, and strengthen the construction of global R&D and industrial capabilities.

Since its establishment, the company has completed multiple rounds of financing totaling over 1.8 billion RMB. From being one of the earliest pioneers in China’s small nucleic acid field to becoming a global leader in siRNA therapy, Ribo Life Science has witnessed the vigorous development of small nucleic acid drug research and has accompanied and led the growth of China’s siRNA industry. Currently, with a highly forward-looking global strategic layout, the company has built multiple R&D centers and a globally integrated small nucleic acid drug development system in Kunshan (Suzhou), Beijing, and Europe. Through independent innovation, it has developed a rich pipeline of siRNA drugs and achieved full lifecycle technology coverage for small nucleic acid drugs from early-stage research to commercialization.

Dr. Zicai Liang, Chairman and CEO of Ribo Life Science, stated: “"With the strong support and high trust from all investors, Ribo Life Science has always adhered to the original aspiration of 'becoming a global leading nucleic acid pharmaceutical enterprise' and achieved comprehensive leapfrog development from breakthroughs in bottleneck technologies to the layout of clinical pipelines. The company will continue to advance its R&D strategy with a global perspective, consolidating its global competitiveness in the small nucleic acid field through the dual drivers of international product development and an independent innovation platform, continuously creating value for shareholders and bringing breakthrough therapeutic solutions to patients."

Dr. Lixin Xu, founding partner of Mingxin Capital, said: "As one of the most disruptive directions in the current biopharmaceutical field, siRNA has significant advantages over traditional drug forms in terms of dosing cycles, patient compliance, R&D cycles, cost, and success rates, making it a key focus of our fund's investment strategy. Ribo Life Science, as a leading company in this field, has multiple clinical-stage pipelines that are globally at the forefront, supported by an international team with a global perspective and top-tier industry expertise. We are honored to lead this round of financing for Ribo Life Science through Jinan Mingxin Industrial Investment Fund. Moving forward, we will firmly support and continuously assist the company in expanding international cooperation to benefit patients worldwide.

Ribo Life Science Focuses on the Research and Development of Small Nucleic Acid (siRNA) Drugs. Ribo Life Science aligns with the innovative frontier of international small nucleic acid technology, committing to the iterative R&D of small nucleic acid chemical modifications and drug delivery technologies. It has established an autonomous and controllable small nucleic acid drug R&D platform that integrates the entire technical chain, supporting all stages of small nucleic acid drug research from early development to industrialization. The company has built a rich product pipeline around cardiovascular, metabolic, liver, kidney, and other therapeutic areas. Among them, the self-developed liver-targeting RiboGalSTARTM delivery technology has advanced multiple products to Phase II clinical trials, with efficacy and safety well-validated clinically. The company adheres to differentiated target and product layouts, possesses an international innovative R&D team, and conducts product R&D and commercialization globally, striving to bring new drug treatments to patients as soon as possible. The company's headquarters is located in Kunshan, Jiangsu, with R&D centers in Beijing and Mölndal, Sweden.